Status:
RECRUITING
Alveolar Macrophage Programming Following Endotoxin Exposure
Lead Sponsor:
National Jewish Health
Conditions:
ARDS, Human
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capi...
Eligibility Criteria
Inclusion
- Written, informed consent
- Age 18-50
Exclusion
- Current or recent illness (past 2 weeks)
- Presence or prior history of cardiac, pulmonary or systemic disease
- Bleeding disorder, use of systemic anticoagulants or antiplatelet therapy
- American Society of Anesthesiology (ASA) class 2 or greater
- Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants)
- Use of any inhaled substance, including tobacco, marijuana, e-cigarrettes, cocaine, methamphetamines, or toxic vapors in the past 3 months or greater than 10 pack-year smoking history
- Alcohol use disorder or greater than 7 drinks/week for women or greater than 14 drinks/week for men in the past 3 months
- Allergy or prior adverse reaction to lidocaine, midazolam or fentanyl
- Abnormal spirometry or electrocardiogram at time of screening
- Pregnant (based on urine pregnancy test) or breast feeding
Key Trial Info
Start Date :
March 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2032
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03859050
Start Date
March 18 2019
End Date
July 1 2032
Last Update
May 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Jewish Health
Denver, Colorado, United States, 80206